Perioperative acute upper gastrointestinal haemorrhage in older patients with hip fracture: Incidence, risk factors and prevention

Alimentary Pharmacology and Therapeutics

Volumn 25, Issue 3, 2007, Pages 297-308

  Fisher, L ^a,b   Fisher, A ^a   Pavli, P ^a   Davis, M ^a  

^a CANBERRA HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

AGED; ARTICLE; BLOOD GROUP O; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIP FRACTURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PEPTIC ULCER; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; UPPER GASTROINTESTINAL BLEEDING;

AGED; AGED, 80 AND OVER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HIP FRACTURES; HUMANS; MALE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROTON PUMPS; RISK ASSESSMENT; RISK FACTORS;

EID: 33846311360     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03187.x     Document Type: Article

References (61)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 2004; 15: 897-902.
2. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ 2005; 331: 1374.
3. Fisher AA, Davis MW, Rubenach SE, et al. Outcomes for older patients with hip fractures: the impact of orthopedic and geriatric medicine cocare. J Orthop Trauma 2006; 20: 172-8; discussion 179-80.
4. Gullberg B, Johnell O, Kanis JA. Worldwide projections for hip fracture. Osteoporos Int 1997; 7: 407-13.
5. Pollard TR, Schwesinger WH, Page CP, Schauer PR, Sirinek KR. Upper gastrointestinal bleeding following major surgical procedures: prevalence, etiology, and outcome. J Surg Res 1996; 64: 75-8.
6. Schuster DP, Rowley H, Feinstein S, McGue MK, Zuckerman GR. Prospective evaluation of the risk of upper gastrointestinal bleeding after admission to a medical intensive care unit. Am J Med 1984; 76: 623-30.
7. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleeding: accessory risk factors and interactions with nonsteroidal anti-inflammatory drugs. Gut 2000; 46: 27-31.
8. Laine L. Treatment of nonvariceal upper GI hemorrhage: what's happening in the real world. Am J Gastroenterol 2004; 99: 1247-9.
9. Kaplan RC, Heckbert SR, Koepsell TD, et al. Risk factors for hospitalized gastrointestinal bleeding among older persons. Cardiovascular Health Study Investigators. J Am Geriatr Soc 2001; 49: 126-33.
10. Wilcox CM Jr. Gastrointestinal considerations in patients with cardiovascular disease using nonopioid analgesics for mild-to-moderate pain or cardioprotection. Am J Cardiol 2006; 97: 17-22.
11. Higham J, Kang JY, Majeed A. Recent trends in admissions and mortality due to peptic ulcer in England: increasing frequency of haemorrhage among older subjects. Gut 2002; 50: 460-4.
12. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165: 784-9.
13. Go MF. Drug injury in the upper gastrointestinal tract: nonsteroidal antiinflammatory drugs. Gastrointest Endosc Clin N Am 2006; 16: 83-97.
14. Barkun AN, Cockeram AW, Plourde V, Fedorak RN. Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999; 13: 1565-84.
15. Lau JY, Chung S. Management of upper gastrointestinal haemorrhage. J Gastroenterol Hepatol 2000; 15 (Suppl.): G8-12.
16. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004; 117 (Suppl. 5A): 63S-71S.
17. Bardou M, Toubouti Y, Benhaberou-Brun D, Rahme E, Barkun AN. Meta-analysis: proton pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther 2005; 21: 677-86.
18. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev 2006; 10 May (Epub ahead of print): CD002094.
19. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. JAMA 1996; 275: 308-14.
20. Pimentel M, Roberts DE, Bernstein CN, Hoppensack M, Duerksen DR. Clinically significant gastrointestinal bleeding in critically ill patients in an era of prophylaxis. Am J Gastroenterol 2000; 95: 2801-6.
21. Allen ME, Kopp BJ, Erstad BL. Stress ulcer prophylaxis in the postoperative period. Am J Health Syst Pharm 2004; 61: 588-96.
22. Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care 2005; 20: 35-45.
23. Metz DC. Preventing the gastrointestinal consequences of stress-related mucosal disease. Curr Med Res Opin 2005; 21: 11-8.
24. Vakil N, Fennerty MB. Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastrooesophageal reflux disease and peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 559-68.
25. Andersson B, Nilsson J, Brandt J, Hoglund P, Andersson R. Gastrointestinal complications after cardiac surgery. Br J Surg 2005; 92: 326-33.
26. Jayaprakash A, McGrath C, McCullagh E, et al. Upper gastrointestinal haemorrhage following cardiac surgery: a comparative study with vascular surgery patients from a single centre. Eur J Gastroenterol Hepatol 2004; 16: 191-4.
27. McSweeney ME, Garwood S, Levin J, et al. Adverse gastrointestinal complications after cardiopulmonary bypass: can outcome be predicted from preoperative risk factors? Anesth Analg 2004; 98: 1610-7 (table of contents).
28. Sharma S. Upper gastrointestinal bleeding after hip and knee arthroplasty. Orthopedics 2006; 29: 255-7.
29. Kinnaird TD, Stabile E, Mintz GS, et al. Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930-5.
30. Kaur S, Cooper G, Fakult S, Lazarus HM. Incidence and outcome of overt gastrointestinal bleeding in patients undergoing bone marrow transplantation. Dig Dis Sci 1996; 41: 598-603.
31. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330: 377-81.
32. Cook DJ, Griffith LE, Walter SD, et al. The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. Crit Care 2001; 5: 368-75.
33. Terdiman JP, Ostroff JW. Gastrointestinal bleeding in the hospitalized patient: a case-control study to assess risk factors, causes, and outcome. Am J Med 1998; 104: 349-54.
34. D'Ancona G, Baillot R, Poirier B, et al. Determinants of gastrointestinal complications in cardiac surgery. Tex Heart Inst J 2003; 30: 280-5.
35. Lewis JD, Shin EJ, Metz DC. Characterization of gastrointestinal bleeding in severely ill hospitalized patients. Crit Care Med 2000; 28: 46-50.
36. Lim CH, Heatley RV. Prospective study of acute gastrointestinal bleeding attributable to anti-inflammatory drug ingestion in the Yorkshire region of the United Kingdom. Postgrad Med J 2005; 81: 252-4.
37. Lanas A. Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Options Gastroenterol 2006; 9: 147-56.
38. Kuyvenhoven JP, Veenendaal RA, Vandenbroucke JP. Peptic ulcer bleeding: interaction between non-steroidal anti-inflammatory drugs, Helicobacter pylori infection, and the ABO blood group system. Scand J Gastroenterol 1999; 34: 1082-6.
39. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective COX-2 inhibitors, traditional non-aspirin NSAIDs, aspirin, and combinations. Gut 2006; 10 May (Epub ahead of print).
40. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331: 1310-6.
41. Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18: 443-9.
42. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-44.
43. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161: 107-10.
44. Lanas A, Serrano P, Bajador E, Fuentes J, Sainz R. Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. Eur J Gastroenterol Hepatol 2003; 15: 173-8.
45. Garcia Rodriguez LA, Hernandez-Diaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570-6.
46. de Abajo FJ, Montero D, Rodriguez LA, Madurga M. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol 2006; 98: 304-10.
47. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther 2006; 23: 937-44.
48. Khapra AP, Rose S. Drug injury in the upper gastrointestinal tract: effects of alendronate. Gastrointest Endosc Clin N Am 2006; 16: 99-110.
49. Adami S, Pavelka K, Cline GA, et al. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 1278-85.
50. Patchett SE, O'Donoghue DP. Pharmacological manipulation of gastric juice: thrombelastographic assessment and implications for treatment of gastrointestinal haemorrhage. Gut 1995; 36: 358-62.
51. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: enhanced efficacy of proton pump inhibitor therapy for peptic ulcer bleeding in Asia - a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005; 21: 1055-61.
52. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs - nice or necessary? Rev Gastroenterol Disord 2004; 4 (Suppl. 4): S33-41.
53. Cook D, Guyatt G, Marshall J, et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998; 338: 791-7.
54. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill: Part 2. Clinical efficacy, safety, and economics. Ann Pharmacother 2005; 39: 1844-51.
55. Faisy C, Guerot E, Diehl JL, Iftimovici E, Fagon JY. Clinically significant gastrointestinal bleeding in critically ill patients with and without stress-ulcer prophylaxis. Intensive Care Med 2003; 29: 1306-13.
56. Kantorova I, Svoboda P, Scheer P, et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepatogastroenterology 2004; 51: 757-61.
57. Mallow S, Rebuck JA, Osler T, et al. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? Curr Surg 2004; 61: 452-8.
58. Yearsley KA, Gilby LJ, Ramadas AV, et al. Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment Pharmacol Ther 2006; 24: 613-9.
59. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-46.
60. Okan A, Tankurt E, Aslan BU, et al. Relationship between non-steroidal anti-inflammatory drug use and Helicobacter pylori infection in bleeding or uncomplicated peptic ulcers: a casecontrol study. J Gastroenterol Hepatol 2003; 18: 18-25.
61. Papatheodoridis GV, Papadelli D, Cholongitas E, et al. Effect of Helicobacter pylori infection on the risk of upper gastrointestinal bleeding in users of nonsteroidal anti-inflammatory drugs. Am J Med 2004; 116: 601-5.